NewGenIvf Group Limited(US:NIVF) Globenewswire·2025-12-02 13:00Core Insights - NewGenIvf Group Limited reported a net income of $17.5 million for the nine months ended September 30, 2025, a significant turnaround from a net loss of $416,400 in the same period of 2024, primarily due to strategic acquisitions and a bargain purchase gain [3][4][10]. Financial Highlights - Total revenues for the nine months ended September 30, 2025, were $3.3 million, down from $4.2 million in the same period of 2024 [10]. - Cost of revenues remained stable at $2.9 million compared to the previous year [10]. - Total other income was $23.20 million, a substantial increase from a loss of $346,748 in the prior year, mainly due to a non-cash bargain purchase gain of $23.44 million from acquisitions [10]. - Basic earnings per share improved to $96.76 from a loss of $205.97 in the same period of 2024 [4][17]. Business Highlights - The company executed a strategic pivot towards acquiring high-value intellectual property, including the acquisition of MicroSort® technology and advanced cytometry IP from Nodexus, resulting in significant bargain purchase gains [3][4][10]. - NewGen is expanding into digital assets, planning to invest up to $30 million in Solana (SOL) and engaging in tokenization of a $2 million private art collection and a $100 million tranche of gold-backed assets [4][5]. - A joint venture in UAE real estate was established, securing a 60% ownership interest in a strategic land development project [4][5]. - The company is exploring a potential reverse merger with SAXA, Inc., which would provide access to mining assets [4][5]. Strategic Initiatives - The company has authorized a share repurchase program of up to $2 million over 24 months, reflecting management's confidence in the company's intrinsic value [4][5]. - A one-for-five reverse stock split was executed on December 1, 2025, to enhance the trading value of its shares [4][5].